Back

Real world prospective one year monocentric follow up study investigating novel lipid lowering agents class proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab

12 April 2019 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Risk Factors and Prevention - Lipids Lipids EAPC Premium Access EuroPrevent 2019

About the speaker

Photo
Mr Madan Raj Poudel

University Clinic OWL, Bielefeld (Germany)

15 More presentations in this session

Presentation thumbnail
Doctor L. Kitova (Plovdiv, BG)
Presentation thumbnail
Doctor S. Cardoso Torres (Porto, PT)
Abstract
Presentation thumbnail
Professor N. Pogosova (Moscow, RU)
Abstract
Presentation thumbnail
Doctor E. Kolesova (St Petersburg, RU)
Abstract
Presentation thumbnail
Doctor J. Gilis-Januszewski (Bad Oeynhausen, DE)
Abstract

Access the full session

Session thumbnail
Poster Session 2 - Risk Factors and Prevention - Lipids

The Event

Event poster

EuroPrevent 2019

12 April 2019 08:30 CET
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Congress Presentation
State-of-the-art lecture on how to keep your arteries young by tackling dyslipidaemia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources